Summary
Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating cell-free tumor DNA and RNA assays utilizing a standard blood sample. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer, colorectal cancer, prostate cancer, pancreaticobiliary cancer, and ovarian cancer. It also provides cerebrospinal fluid tumor cell and ctDNA and ctRNA testing services to medical oncologists, neuro-oncologists, surgical oncologists, urologists, pulmonologists, pathologists, and other physicians; clinical trial and research services to pharmaceutical companies, biopharmaceutical companies and clinical research organizations; and RT-PCR testing services for COVID-19. The company has a collaboration with CLEARED4 to develop a system for tracking and managing COVID-19 testing requirements and test results for its customers; and with Protean BioDiagnostics, Inc. to research the ability of its Target Selector molecular assay to determine EGFR status in NSCLC patients. Biocept, Inc. was incorporated in 1997 and is headquartered in San Diego, California.
History
Founded in 2002, Biocept was turned into a publicly traded company in 2014. With a focus on providing highly sensitive and specific molecular analysis services of debulking and confirming therapeutic targets to improve clinical outcomes, Biocept is dedicated to cancer diagnostics and therapeutics.
Mission
Biocept’s mission is to be a leader in transforming the diagnosis and treatment of cancer through the development and commercialization of novel laboratory assays that provide physicians with clinically actionable diagnostics and therapeutic insights.
Vision
At Biocept, we strive to create an environment of excellence and create lifesaving treatments and diagnostics that transform the way cancer is treated.
Key Team
Mr. Pavel Tsinberg (Director of Technology Devel.)
Dr. Soon Kap Hahn Ph.D. (Founder)
Dr. Philippe J. Marchand Ph.D. (Chief Operating Officer)
Mr. Darrell Taylor Esq. (Chief Legal Officer, Chief Compliance Officer, Corp. Sec. & Registered In-House Counsel)
Mr. David S. Moskowitz R.Ph., MBA (VP of Strategy & Corp. Communications)
Mr. Michael Terry (Sr. VP of Corp. Devel.)
Antonio Paternostro (VP of Sales)
Recognition and Awards
Biocept has received many awards, including the Red Herring Top 100 Americas Award, the Life Science Leader Magazine 100 Great Places to Work Award, and the San Diego Business Journal Cities of Life Bio Award.
References
